首页 > 市场调查报告书 > 製药

临床实验

嗜中性白血球低下症市场规模、份额、成长分析（依治疗类型、风险因子、药物类别及地区划分）－2025-2032年产业预测

市场调查报告书

商品编码

1854238

嗜中性白血球低下症市场规模、份额、成长分析（依治疗类型、风险因子、药物类别及地区划分）－2025-2032年产业预测

Febrile Neutropenia Market Size, Share, and Growth Analysis, By Treatment Type, By Risk Factors, By Drug Class, By Region - Industry Forecast 2025-2032

出版日期: 2025年10月22日 | 出版商:

SkyQuest | 英文 185 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球嗜中性白血球低下症市场预计在 2023 年达到 119 亿美元，从 2024 年的 125.5 亿美元成长到 2032 年的 192.7 亿美元，在预测期（2025-2032 年）内以 5.5% 的复合年增长率。

发烧性嗜中性白血球低下症市场主要受全球癌症发生率上升的影响，加剧了化疗相关嗜中性嗜中性白血球低下併发症的风险。化疗和免疫抑制疗法的日益普及推动了对有效预防措施的需求。此外，长效粒细胞集落刺激因子（G-CSF）疗法的进展以及生物相似药的核准正在改善治疗的可及性，尤其是在已开发市场和新兴市场。然而，仍有许多挑战，例如生物相似药的高成本，这阻碍了其在中低收入地区的应用。此外，长期使用G-CSF引发了人们对持续副作用的担忧。对抗生素抗药性的担忧以及生物相似药核准监管状况的不确定性进一步加剧了市场格局的复杂性。

全球嗜中性白血球低下症市场驱动因素

嗜中性白血球低下症症市场的主要驱动因素是癌症发生率的上升和人口老化，老年人更容易罹患各种恶性肿瘤。随着癌症治疗，尤其是化疗，变得更加积极和广泛，嗜中性白血球低下症（一种以发烧和嗜中性白血球为特征的严重併发症）的风险也在增加。这种日益增长的发病率推动了对有效预防疗法和治疗方案的需求，促进了药物研发创新，并增加了医疗保健支出。此外，公众意识的提高和诊断技术的进步也有助于嗜中性白血球低下症的早期发现和治疗，进一步推动了市场成长。

全球嗜中性白血球低下症市场的限制因素

全球嗜中性白血球低下症症市场的主要限制因素之一是创新治疗和支持性护理药物研发及生产高成本。这种经济负担往往限制了病患的用药可近性，尤其是在医疗资源有限的中低收入国家。此外，临床试验的复杂性和严格的监管核准流程会延缓新疗法的上市，进一步阻碍市场成长。而且，医疗专业人员对嗜中性白血球低下症的认识和了解不足，会导致漏诊和治疗不足，加剧该市场面临的挑战。

全球嗜中性白血球低下症市场趋势

由于生物相似药在癌症支持治疗中日益普及和应用，全球嗜中性白血球低下症症市场正经历着变革性的变化。Filgrastim和Pegfilgrastim等生物相似药的核准不断增加，提高了治疗的可近性，尤其是在新兴市场，在这些市场，经济有效的治疗方案对于实现公平的癌症治疗至关重要。这一趋势促进了医疗服务提供者之间的良性竞争，最终将改善患者预后并降低医疗成本。随着全球医疗体系适应这些创新，市场有望迎来显着扩张，反映出人们普遍致力于改善癌症基本治疗方法的可近性并提高患者的生活品质。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2024 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2024 年）
主要企业简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2022-2024年收益年比比较

主要企业简介

Amgen Inc.（USA）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Teva Pharmaceutical Industries Ltd.（Israel）
Viatris Inc.（USA）
Biocon Biologics Ltd（India）
Coherus BioSciences, Inc.（USA）
Kyowa Kirin Co., Ltd.（Japan）
Spectrum Pharmaceuticals, Inc.（USA）
Hanmi Pharmaceutical Co., Ltd.（South Korea）
BeyondSpring Inc.（USA）
G1 Therapeutics, Inc.（USA）
Partner Therapeutics, Inc.（USA）
Cellerant Therapeutics, Inc.（USA）
Fresenius Kabi（Germany）
Intas Pharmaceuticals Ltd.（India）
Gedeon Richter Plc.（Hungary）
Aurobindo Pharma Limited（India）
Amneal Pharmaceuticals, Inc.（USA）
Merck & Co., Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35I2453

Global Febrile Neutropenia Market size was valued at USD 11.9 billion in 2023 and is poised to grow from USD 12.55 billion in 2024 to USD 19.27 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The febrile neutropenia market is primarily influenced by the rising global incidence of cancer, which escalates the risk of neutropenic complications related to chemotherapy. The increasing use of chemotherapy and immunosuppressive therapies underscores a heightened demand for effective preventive measures. Furthermore, advancements in long-acting G-CSF therapies and regulatory approvals for biosimilars enhance treatment accessibility, particularly in developed and emerging markets. However, significant challenges persist, including the high costs associated with biosimilars that hinder availability in low- and middle-income regions. Additionally, limited awareness and late diagnoses contribute to hospitalizations at more severe stages, while chronic G-CSF use raises ongoing side effects concerns. The looming fear of antibiotic resistance and regulatory uncertainties regarding biosimilar approvals further complicate the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Febrile Neutropenia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Febrile Neutropenia Market Segments Analysis

Global Febrile Neutropenia Market is segmented by Treatment Type, Risk Factors, Drug Class and region. Based on Treatment Type, the market is segmented into Prophylactic Treatment and Therapeutic Treatment. Based on Risk Factors, the market is segmented into Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia and Genetic Disorders. Based on Drug Class, the market is segmented into Antibiotics, Granulocyte Colony-Stimulating Factors, Antifungals and Antivirals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Febrile Neutropenia Market

A key market driver for the global febrile neutropenia market is the increasing prevalence of cancer and the growing aging population, which is more susceptible to various types of malignancies. As cancer treatments, particularly chemotherapy, become more aggressive and widespread, the risk of febrile neutropenia-a severe complication characterized by fever and low neutrophil counts-escalates. This rising incidence drives demand for effective prophylactic therapies and treatment options, fueling innovations in drug development and increasing healthcare expenditure. Additionally, heightened awareness and improved diagnostic techniques contribute to earlier detection and management of febrile neutropenia, further propelling market growth.

Restraints in the Global Febrile Neutropenia Market

One of the key market restraints for the global febrile neutropenia market is the high cost associated with the development and manufacture of innovative therapeutics and supportive care medications. This financial burden often limits accessibility for patients, particularly in low- and middle-income countries where healthcare resources are constrained. Additionally, the complexity of clinical trials and stringent regulatory approval processes can delay the introduction of new treatments, further inhibiting market growth. Furthermore, the lack of awareness and understanding of febrile neutropenia among healthcare providers may lead to underdiagnosis and under-treatment, compounding the challenges faced in this market.

Market Trends of the Global Febrile Neutropenia Market

The Global Febrile Neutropenia market is experiencing a transformative shift driven by the increased acceptance and integration of biosimilars in supportive cancer care. The growing approval of biosimilars like filgrastim and pegfilgrastim is enhancing treatment accessibility, particularly in developing markets, where cost-effective options are crucial for equitable cancer care. This trend fosters healthy competition among providers, ultimately leading to better patient outcomes and improved healthcare affordability. As healthcare systems globally adapt to these innovations, the market is poised for significant expansion, reflecting a broader commitment to increasing access to essential cancer care therapies and enhancing the quality of life for patients.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Febrile Neutropenia Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Prophylactic Treatment
Therapeutic Treatment

Global Febrile Neutropenia Market Size by Risk Factors & CAGR (2025-2032)

Market Overview
Chemotherapy-Induced Neutropenia
Transplant-Related Neutropenia
Genetic Disorders

Global Febrile Neutropenia Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Antibiotics
Granulocyte Colony-Stimulating Factors
Antifungals
Antivirals

Global Febrile Neutropenia Market Size & CAGR (2025-2032)

North America (Treatment Type, Risk Factors, Drug Class)
- US
- Canada
Europe (Treatment Type, Risk Factors, Drug Class)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Risk Factors, Drug Class)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Risk Factors, Drug Class)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Risk Factors, Drug Class)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon Biologics Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus BioSciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spectrum Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hanmi Pharmaceutical Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BeyondSpring Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
G1 Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Partner Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellerant Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gedeon Richter Plc. (Hungary)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments